SCAI Therapeutics Confirms Efficacy and Safety of Dry Eye Drops in Phase 2 Clinical Trials

SCAI Therapeutics (Kim Chul-hwan) announced on the 19th that it has completed the phase 2 clinical trial of its new dry eye treatment, 'SCAI-001', and confirmed its efficacy and safety. 

This clinical trial was conducted to evaluate the efficacy and safety of SCAI-001 compared to the existing dry eye treatment, 'Restasis®', in patients with moderate to severe dry eye. The trial was conducted on 116 dry eye patients at 11 clinical trial institutions in Korea, including Pusan ​​National University Hospital. 

As a result, statistically significant improvements were confirmed in objective signs such as tear volume and corneal staining test scores, and subjective symptoms such as the Ocular Discomfort Index (OSDI) at week 12.

SCAI-001 is a dry eye eye drop that applies Sky Therapeutics' proprietary MOASIS® technology, a bioavailability enhancement platform technology, to cyclosporine, a dry eye treatment substance. It is characterized by containing only 20-40% of the active ingredient compared to the existing treatment, Restasis, while reducing excipients by up to 90%.

SCAI Therapeutics plans to present the results of this Phase 2 clinical trial at international ophthalmology conferences, including the Korean Ophthalmological Society conference to be held in Jeju Island in March. By securing consistent results across efficacy indicators, SCAI Therapeutics is expected to gain momentum in pursuing Phase 3 clinical trials and technology licensing agreements with domestic and international companies. 

Meanwhile, SCAI Therapeutics secured KRW 33.4 billion in Series B funding in 2022.

As a follow-up pipeline, it is developing an eye drop treatment for macular degeneration using its Moasis® technology.

Original article source: HELLO DD (www.hellodd.com)

Source link: http://www.hellodd.com/news/articleView.html?idxno=103159